{"id":"exp1-data-minimalism","title":"Data Minimalism vs. Data Maximalism in Rare Disease Drug Repurposing","assumption":"More comprehensive multi-modal datasets always improve repurposing predictions","hypothesis":"Minimal but highly curated datasets achieve superior actionable predictions compared to comprehensive multi-modal approaches","evaluationPlan":"Controlled comparison between minimal curated dataset (n=500 high-confidence associations) vs maximal dataset (n=50,000+ multi-modal features) using identical ML architectures across 10 rare diseases. Evaluation includes prediction accuracy, clinical actionability score, expert agreement, and implementation feasibility.","implications":"Could unlock repurposing for ultra-rare conditions with extremely limited data by focusing on data quality over quantity","relatedWork":"Challenges data maximalism assumptions in drug discovery AI literature","milestones":"Month 1: Dataset curation, Month 2: Model training, Month 3: Clinical expert evaluation","successCriteria":"Minimal datasets show comparable accuracy (±5%) but superior actionability (>20% improvement) and expert acceptance (>60% preference)","priority":"high","status":"proposed","notes":"Core experiment testing fundamental data assumption","createdDate":"2025-08-13T05:15:00.000Z"}
{"id":"exp2-actionability-first","title":"Accuracy-First vs. Actionability-First AI Design","assumption":"Predictive accuracy is the primary success metric for AI systems","hypothesis":"AI systems optimized for clinical actionability produce better real-world outcomes than accuracy-optimized models","evaluationPlan":"Deploy both accuracy-optimized and actionability-optimized AI systems with clinical partners. Measure clinical adoption rate, decision confidence, time from prediction to clinical action, and long-term outcomes through randomized deployment.","implications":"Could bridge the gap between AI predictions and clinical implementation by prioritizing clinical utility over raw performance metrics","relatedWork":"Challenges accuracy-first optimization paradigm in medical AI literature","milestones":"Month 1: Actionability framework design, Month 3: Model development, Month 6: Clinical deployment","successCriteria":"Actionability-first models achieve >30% higher clinical adoption rate despite potentially 5-10% lower raw accuracy","priority":"high","status":"proposed","notes":"Critical for clinical translation success","createdDate":"2025-08-13T05:15:00.000Z"}
{"id":"exp3-cross-disease","title":"Cross-Disease Pattern Learning vs. Disease-Specific Modeling","assumption":"Each rare disease requires custom computational approaches","hypothesis":"Meta-learning approaches leveraging shared patterns across rare diseases outperform disease-specific models","evaluationPlan":"Implement Model-Agnostic Meta-Learning (MAML) across 20 rare diseases with varying pathophysiology. Compare few-shot learning performance, cross-disease generalization, and mechanistic interpretability between meta-learned and disease-specific models.","implications":"Could enable repurposing for diseases with insufficient individual datasets by leveraging cross-disease mechanistic patterns","relatedWork":"Challenges disease-specific modeling assumption in precision medicine literature","milestones":"Month 1: Disease selection and data preparation, Month 3: MAML implementation, Month 4: Cross-disease validation","successCriteria":"Meta-learning achieves >40% better few-shot performance (<10 examples) and identifies interpretable shared mechanistic patterns","priority":"medium","status":"proposed","notes":"Enables ultra-rare disease applications","createdDate":"2025-08-13T05:15:00.000Z"}
{"id":"exp4-parallel-validation","title":"Parallel vs. Sequential Validation Strategies","assumption":"Drug validation must follow sequential preclinical → clinical stages","hypothesis":"Parallel validation using real-world evidence accelerates repurposing without compromising safety","evaluationPlan":"Compare time-to-treatment and safety outcomes between traditional sequential validation and parallel validation using real-world evidence, EHR data, and accelerated clinical protocols. Partner with regulatory agencies for acceptance evaluation.","implications":"Could dramatically reduce time-to-treatment for rare disease patients while maintaining safety standards","relatedWork":"Challenges sequential validation paradigm in drug development literature","milestones":"Month 3: Regulatory engagement, Month 6: Parallel framework implementation, Month 12: Outcome comparison","successCriteria":"Parallel validation reduces time-to-treatment by 40-60% while maintaining equivalent safety signal detection (>95% sensitivity)","priority":"medium","status":"proposed","notes":"Requires regulatory partnership and long timeline","createdDate":"2025-08-13T05:15:00.000Z"}
{"id":"exp5-human-ai-collab","title":"Human-AI Collaboration vs. Fully Automated Approaches","assumption":"AI should minimize human bias and replace expert judgment","hypothesis":"Hybrid human-AI systems outperform fully automated approaches for complex repurposing decisions","evaluationPlan":"Design collaborative interface for clinician-AI drug repurposing decisions. Conduct comparative evaluation study with rare disease experts comparing automated vs collaborative systems on matched clinical scenarios.","implications":"Could leverage irreplaceable rare disease expertise while scaling discovery through strategic human-AI collaboration","relatedWork":"Challenges AI supremacy assumption in medical decision-making literature","milestones":"Month 1: Interface design, Month 2: Expert recruitment, Month 4: Comparative evaluation","successCriteria":"Collaborative systems achieve >25% higher decision quality scores and >50% higher clinical implementation rate","priority":"high","status":"proposed","notes":"Critical for expert acceptance and adoption","createdDate":"2025-08-13T05:15:00.000Z"}